Everest Medicines to Announce Half-Year 2021 Interim Results
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, July 29, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
SHANGHAI, July 20, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
SHANGHAI, July 13, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent
SHANGHAI, July 12, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, May 20, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, May 17, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, May 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inGreater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS) inSouth...
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
SHANGHAI, April 15, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer
SHANGHAI, April 14, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020
SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections
SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021
SHANGHAI, March 19, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced ...
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines
